Venetoclax plus ibrutinib appears to suit elderly and high-risk patients with CLLMay 29, 2019Leukemia, Myelodysplasia, Transplantation
Daratumumab regimen shows benefit in transplant-ineligible myelomaMay 29, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
FDA approves lenalidomide/rituximab for previously treated FL, MZLMay 29, 2019Lymphoma & Plasma Cell Disorders
Genetic analysis identifies prognostic markers in CLLMay 28, 2019Leukemia, Myelodysplasia, Transplantation
Family history plays a large role in bleeding disorder diagnosis in womenMay 17, 2019Bleeding Disorders
NGS comparable to FC for minimal residual disease assessmentMay 17, 2019ALLPediatricsLeukemia, Myelodysplasia, Transplantation
Lenalidomide may reduce risk of progression from SMM to MMMay 16, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Trial follow-up spotlights survival gains in follicular lymphomaMay 16, 2019Lymphoma & Plasma Cell Disorders
FDA approves venetoclax/obinutuzumab combo for CLLMay 15, 2019Leukemia, Myelodysplasia, Transplantation
FDA panel not ready to recommend quizartinib approval for FLT3-ITD+ AMLMay 14, 2019AMLLeukemia, Myelodysplasia, Transplantation
